Emerging Therapies Reshape the Open-Angle Glaucoma Treatment Market Outlook

Earlier identification can increase the duration over which patients receive treatment and monitoring. As screening programs become more accessible, the diagnosed and treated patient population may continue to expand, strengthening opportunities across the open-angle glaucoma market.

Evolving Drug Classes and Treatment Approaches

Intraocular pressure reduction remains the central objective of open-angle glaucoma treatment. Established therapies include FP receptor agonists such as ZIOPTAN and XALATAN, beta-blockers such as timolol, alpha agonists such as brimonidine, and carbonic anhydrase inhibitors such as dorzolamide.

Newer therapies are introducing alternative mechanisms of action. OMLONTI, an EP2 receptor agonist, and RIPASUDIL, a Rho kinase inhibitor, provide additional approaches for improving aqueous humor outflow. Citicoline is another emerging option that has been investigated for mechanisms beyond conventional IOP reduction, including effects associated with glutathione stimulation.

Long-acting treatment options are also gaining attention. DURYSTA, a bimatoprost intracameral implant, was developed to provide sustained IOP control while potentially reducing dependence on daily eye drops.

Learn more about the open-angle glaucoma treatment options @ https://www.delveinsight.com/sample-request/open-angle-glaucoma-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

MIGS Strengthens the Procedural Treatment Landscape

Minimally invasive glaucoma surgery is becoming an increasingly important component of the treatment landscape. Devices such as iStent, Hydrus Microstent, and Xen Gel Stent provide procedural options for patients requiring additional intervention.

MIGS approaches are designed to offer less invasive alternatives to traditional filtering procedures and may provide benefits related to safety, recovery, and treatment integration. Continued adoption of these technologies could contribute to the broader evolution of glaucoma management.

Pipeline Therapies Could Reshape Competition

The competitive landscape is becoming increasingly dynamic as multiple companies advance novel open-angle glaucoma candidates.

Omikron Italia's Citicoline is being evaluated in Phase II clinical development. Its proposed multifaceted activity includes preservation of cardiolipin and sphingomyelin, restoration of phosphatidylcholine, stimulation of glutathione production, reduction of glutamate levels, and support for mitochondrial function.